RT Journal Article
SR Electronic
T1 Effect of losartan on hospitalized patients with COVID-19-induced lung injury: A randomized clinical trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.25.21262623
DO 10.1101/2021.08.25.21262623
A1 Michael A. Puskarich
A1 Nicholas E. Ingraham
A1 Lisa H Merck
A1 Brian E Driver
A1 David A. Wacker
A1 Lauren Page Black
A1 Alan E. Jones
A1 Courtney V. Fletcher
A1 Andrew M. South
A1 Andrew C. Nelson
A1 Thomas A Murray
A1 Christopher J. Tignanelli
A1 Christopher Lewandowski
A1 Joseph Farhat
A1 Justin L. Benoit
A1 Dana Byrne
A1 Alex Hall
A1 Ronald A. Reilkoff
A1 Michelle H. Biros
A1 Kartik Cherabuddi
A1 Jeffrey G. Chipman
A1 Timothy W. Schacker
A1 Tyler Bold
A1 Kenneth Beckman
A1 Ryan Langlois
A1 Matthew T. Aliota
A1 Faheem W. Guirgis
A1 James Galbriath
A1 Margaret Beyer
A1 Chas Salmen
A1 Brian Roberts
A1 David Wright
A1 Helen T. Voelker
A1 Joseph S. Koopmeiners
YR 2021
UL http://medrxiv.org/content/early/2021/08/28/2021.08.25.21262623.abstract
AB Background SARS-CoV-2 viral entry may disrupt angiotensin II (Ang II) homeostasis in part via ACE2 downregulation, potentially contributing to COVID-19 induced lung injury. Preclinical models of viral pneumonias that utilize ACE2 demonstrate Ang II type 1 receptor (AT1R) blockade mitigates lung injury, though observational COVID-19 data addressing the effect of AT1R blockade remain mixed.Methods Multicenter, blinded, placebo-controlled randomized trial of losartan (50 mg PO twice daily for 10 days) versus placebo. Hospitalized patients with COVID-19 and a respiratory sequential organ failure assessment score of at least 1 and not already taking a renin-angiotensin-aldosterone system (RAAS) inhibitor were eligible. The primary outcome was the imputed partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2) ratio at 7 days. Secondary outcomes included ordinal COVID-19 severity, oxygen, ventilator, and vasopressor-free days, and mortality. Losartan pharmacokinetics (PK) and RAAS components [Ang II, angiotensin-(1–7) (Ang-(1–7)), ACE, ACE2] were measured in a subgroup of participants.Findings From April 2020 - February 2021, 205 participants were randomized, 101 to losartan and 104 to placebo. Compared to placebo, losartan did not significantly affect PaO2/FiO2 ratio at 7 days [difference of -24.8 (95% -55.6 to 6.1; p=0.12)]. Losartan did not improve any secondary clinical outcome, but worsened vasopressor-free days. PK data were consistent with appropriate steady-state concentrations, but we observed no significant effect of losartan on RAAS components.Interpretation Initiation of orally administered losartan to hospitalized patients with COVID-19 and acute lung injury does not improve PaO2 / FiO2 ratio at 7 days. These data may have implications for ongoing clinical trials.Trial Registration Losartan for Patients With COVID-19 Requiring Hospitalization (NCT04312009), https://clinicaltrials.gov/ct2/show/NCT04312009Competing Interest StatementFunding: The study was primarily funded by the Bill and Melinda Gates Foundation. AMS reports support from (NIH NHLBI K23HL148394; L40HL148910; R01HL146818); Pharmacokinetic data analyses were supported by NIH R01AI124965 (CVF). The funder had no role in the analysis, interpretation of results, or decision to publish.Clinical TrialNCT04312009Funding StatementFunding: The study was primarily funded by the Bill and Melinda Gates Foundation. AMS reports support from (NIH NHLBI K23HL148394; L40HL148910; R01HL146818); Pharmacokinetic data analyses were supported by NIH R01AI124965 (CVF). The funder had no role in the analysis, interpretation of results, or decision to publish.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The protocol was approved by a central institutional review board (Advarra, Pro00042757) and conducted following good clinical practice guidelines under the oversight of an independent data safety monitoring board. All participants or their legally authorized representatives (LARs) provided written electronic informed consent. The trial was conducted under the authority of the Food and Drug Administration (IND 148365) and registered on clinicaltrials.gov prior to initialization (NCT043112009).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDeidentified data will be fully available upon peer reviewed publication at the Data Repository for the University of Minnesota